Pfizer (PFE) PT Lowered to $36 at JPMorgan

JPMorgan analyst Chris Schott lowered the price target on Pfizer (NYSE: PFE) to $36.00 (from $37.00) while maintaining a Neutral rating.

The analyst comments "We see a clear inflection in growth for Pfizer after the Lyrica patent expiration in 2019 with a reacceleration of the company’s organic top- and bottom-line growth in the 2020-2025 period (top-line growth of ~5% expected to be above Major Pharma). However, we remain Neutral with valuation reflecting visible near-term growth and another major patent cycle post-2025."

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Tata Motors Passenger Vehicles (TMPV:IN) PT Raised to INR375 at ICICI Securities